Studies, Senator Prompt FDA To Look At Chantix

Law360, New York (June 2, 2008, 12:00 AM EDT) -- Amid reports of numerous health problems linked to Pfizer's anti-smoking drug Chantix, the U.S. Food and Drug Administration is taking a close look at a new study and planning to meet with a senator who has expressed concerns about the drug.

The study by the nonprofit Institute for Safe Medication Practices studies, released in late May, linked Chantix, which is already subject to FDA warnings for increased risk of depression and suicide, to heart rhythm disturbances, seizures and loss of consciousness.

That drew the ire of...
To view the full article, register now.